Corporate News
Clearmind Medicine Inc. (ticker: CMND) experienced a decline of –2.17 % in its share price during the 24‑hour trading window that concluded at 01:34 PM Central Europe on Monday, 26 April 2024. At the close of that session, the stock was trading at USD 5.92 on the Canadian National Stock Exchange, with a total supply of 507.4 k shares currently available for trading.
The company’s market capitalization stands at USD 3 million, reflecting the relatively small size of the firm within the pharmaceutical sector. In the most recent 24‑hour period, approximately USD 49.3 k worth of shares changed hands, underscoring modest liquidity relative to larger peers.
Comparatively, the share price has fallen by –9.41 % since the end of the previous month, indicating a broader downward trend in recent trading activity. Over the longer term, the simple moving average calculated over the past 200 days is USD 52.49, suggesting that the current trading level is well below the medium‑term average.
In the context of recent market extremes, the highest price recorded for CMND over the past 52 weeks was USD 3,840, achieved on 29 October 2025. The lowest price during that same period was USD 5.25, observed on 5 October 2026. These figures illustrate a significant volatility range for the company’s stock.
Comparative Performance of Peer Stocks
The 24‑hour performance of several related stocks provides additional context for the current market environment:
| Company | Ticker | 24‑Hour Performance | Current Price (CAD) | Market Capitalization (CAD) |
|---|---|---|---|---|
| Cleghorn Minerals | CZZ.V | Flat 0 % | 0.10 | 5 million |
| Tru Precious Metals | TRU.V | Flat 0 % | 0.03 | 5 million |
| Vision Marine | VMAR.V | Down –33.91 % | 0.76 | 5 million |
| Pharmather | PHRM.CN | Up 20 % | 0.06 | 5 million |
| Sato | SATO.V | Flat 0 % | 0.06 | 5 million |
These figures show that while Clearmind Medicine’s decline is modest relative to its peers, Vision Marine experienced a significant drop, and Pharmather recorded a notable gain. The relative stability of Cleghorn Minerals, Tru Precious Metals, and Sato suggests that sector‑specific dynamics are influencing investor sentiment.
Company Overview
Clearmind Medicine Inc. is a Canadian pharmaceutical company headquartered in Canada. The firm operates exclusively on the Canadian National Stock Exchange, focusing on the development and commercialization of novel therapeutic agents. Its relatively low market capitalization and limited trading volume position it as a niche player within the broader pharmaceutical landscape.
Investors monitoring Clearmind Medicine should consider the company’s current valuation relative to its 200‑day moving average and the broader volatility exhibited in the past year. Additionally, the comparative performance of peer stocks indicates that while some industry peers are stable, others are experiencing more pronounced swings, which may impact overall sector sentiment.